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Abstract
Objectives—We constructed CD4 count gain percentile distributions standardized by baseline 
CD4 count and assessed the association between poor CD4 count gain and subsequent death and 
virological failure on antiretroviral treatment (ART).
Design—Secondary analysis of ten years of clinical data from a cohort of adults initiated on ART 
at the Themba Lethu clinic in Johannesburg, South Africa.
Methods—The generalized additive model for location, scale and shape was used to construct 
percentile curves for CD4 count gain standardized by baseline CD4 count in the first 28 months of 
ART. Cox proportional models were used to assess the association between lower percentiles 
(<50th) of CD4 count gain and subsequent death and virological failure.
Results—Among 9640 non-pregnant adults 7406, with available CD4 count results for CD4 gain 
calculation at 4months of ART, 843 (8.7%) died subsequently and 1101 (11.4%) experienced 
virologic failure, respectively. For CD4 gains below the 3rd percentile, the adjusted hazard ratios 
at different time points ranged between 2.72 and 5.73 for death and between 1.48 to 6.93 for 
virologic failure. The CD4 percentile curves revealed a gradient of increasing risk of subsequent 
death and virological failure with lower CD4 gain percentiles and increasing time on ART, and 
were more informative than the WHO criteria for immunological failure or current CD4 count.
Conclusions—Percentile curves of CD4 count gain provide a simple tool for health care 
workers in low resource settings to monitor response to ART with improved information regarding 
risk of death and virological failure compared to current WHO criteria for immunological failure.
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INTRODUCTION
Access to antiretroviral therapy (ART) in low- and middle-income countries has 
dramatically improved in recent years. At the end of 2012, 9.7 million people living with 
HIV were receiving ART in low- and middle-income countries [1]. Monitoring individuals 
receiving ART is important to ensure successful treatment, identify adherence problems and 
individuals at high risk of poor treatment outcomes, and to determine whether antiretroviral 
regimens should be switched in case of treatment failure [2].
Clinical trials have shown that viral load monitoring is a more sensitive and early indicator 
of treatment failure than CD4 monitoring [3–5]. In the United States [6], monitoring viral 
load is therefore recommended every 4–8 weeks until viral suppression is achieved and 
every 3 to 4 months thereafter during the first 2 years of ART. In addition, CD4 count is 
monitored every 3 to 6 months. The measurement of viral load requires expensive and 
sophisticated technologies that are not always feasible or affordable, particularly in 
resource-poor settings where the burden of disease is greatest. Where viral load is not 
routinely available, the 2013 WHO antiretroviral guidelines recommend regular CD4 count 
monitoring [2].
Despite highly specific and widely accepted definitions of viral failure, i.e. viral load ≥1000 
copies/ml (WHO) or ≥200 copies/ml (US) on two consecutive viral load measurements 3 
months apart [2, 6], there is no consensus definition for suboptimal immunologic response. 
Studies have used multiple definitions, most commonly failure to increase CD4 counts 
above a specific threshold over a specific period of time (e.g., >200 cells/mm3 by 6 months 
on ART) or an increase in CD4 counts above baseline levels by a certain threshold over a 
given time period (e.g., <0, 0–49, 50–99 and ≥200 cells/mm3 by 6 months on ART) [7]. The 
WHO defines immunological failure as a CD4 count at or below baseline level or 
persistence of CD4 count below 100 cells/mm3 [2]. All these definitions ignore the fact that 
changes in CD4 count are not homogeneous across baseline levels of CD4 count. 
Furthermore, studies assessing the predictive value of the WHO definition have shown low 
sensitivity and low positive predictive values for predicting virological failure, particularly 
in patients starting ART at higher (>350) CD4 count levels [8].
Defining cut-points for indicators that are continuous in nature (e.g. CD4 count) and for 
which changes are strongly correlated to values of another continuous indicator (e.g. time on 
ART) is not uncommon in medicine. One example is that of monitoring changes in weight 
among children while accounting for variation with age. This is usually addressed by 
standardizing the distribution of the indicator of interest (e.g. CD4 count) by the continuous 
cofactor (e.g. time on ART) and using percentile distributions or cut-offs such as minus two 
standard deviations [9–14].
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The aim of this study was to construct distributions of cumulative CD4 cells gains from 
ART initiation to 4, 10, 16, 22, and 28 months post-ART initiation, standardized by baseline 
CD4 count. We also assess the correlation of lower centiles (3rd, 10th, 25th, 33rd, and 50th) of 
the distributions with subsequent mortality and virological failure and the accuracy of those 
centiles for early identification of patient at risk of virological failure and death.
METHODS
Data and data source
The data was collected from the Themba Lethu Clinic Cohort, an open cohort of HIV-
infected adults (≥ 18 years) who receive ART at a public ART clinic in Johannesburg, South 
Africa [15, 16]. At baseline, ART eligibility is assessed clinically and by CD4 count. In line 
with national guidelines, viral load is not determined at baseline. Patients initiated on ART 
are monitored by CD4 count and viral load at 4 months post ART initiation and every 6 
months thereafter, and at any other time if clinically needed. Patients who fail to achieve 
viral suppression by month 4 are scheduled for monthly visits until viral suppression is 
achieved. Patients who miss a clinic visit are actively traced by telephone. Lost to follow-up 
is defined as being four months late for last scheduled clinic visit. Mortality is ascertained 
via family, hospital report, and linkage with the South African National Vital Registration 
Infrastructure Initiative, a system estimated to have 90% sensitivity for adults [17].
Study population
All non-pregnant adults with baseline CD4 count measure < 500 cell/mm3 who initiated 
ART between April 1, 2004 and April 1, 2014 and had at least one follow-up CD4 count 
result were included in the analysis.
Definitions
Baseline CD4 was defined as the closest CD4 count measurement collected 6 months before 
to seven days after ART initiation.
The change in CD4 count at each time point was determined using the closest measure that 
was collected within ±6 weeks of the time points of interest (4, 10, 16, 22, and 28 months of 
ART) and calculated by subtracting the baseline value from the value at the time point of 
interest. Assuming a linear increase in CD4 count over time within each time interval, we 
then estimated the CD4 count gain at the time point of interest by dividing the observed 
change in CD4 count by the real time interval in months and multiplying this by 4 for the 4 
month time point or by 6 for all other time points.
Viral failure was defined as the first of two consecutive viral loads >1000 RNA copies/ml 
after initial suppression or as not achieving viral suppression after at least 12 months on 
ART.
Construction of baseline-standardized distributions of CD4 cells gain at each time point
To obtain the distribution of CD4 gain at each time point of interest, methods similar to 
those used by the WHO to construct international growth curves in children [11] were 
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adapted and used as described previously [14]. The changes in CD4 cells count for each 
time point was regressed on baseline values using the generalized additive model for 
location, scale and shape, a method that requires a parametric distribution assumption for the 
response variable (CD4 gain over time) while allowing the modeling of the distribution 
parameters as nonparametric (smooth) functions of the explanatory variable (baseline CD4 
count) [18]. For CD4 cell gain at each time point, we assumed a Box-Cox power exponential 
distribution with four parameters relating to location (µ, median), scale (σ, coefficient of 
variation), skewness (υ, transformation for symmetry), and kurtosis (τ, power exponential 
parameter), respectively [19]. The number of degrees of freedom (df) was determined by a 
step-down procedure in a training set which consisted of a random sub-sample of 60% of the 
total data set. We started with the simplest model that included baseline CD4 count and the 
fitting of µ and σ curves while keeping df(υ) and df(τ) fixed at zero. We searched for the 
df(µ) and df(σ) that minimized the global deviance as indicated by the generalized Akaike 
Information Criterion (with penalty 3 for each df used). In the next step, using the selected 
df(µ) and df(σ), we sequentially searched for the df(υ) and df(τ) that minimized the global 
deviance. In the last step, Q statistic [20] and worm plots [21] were used to fine tune the 
selected df(µ), df(σ), df(υ), and df(τ) [19]. To facilitate the convergence of the models and 
obtain smoother curves [12, 18, 22], extreme values of CD4 count, i.e. values that looked far 
apart on visual inspection, were set to missing during the construction of the standardized 
distributions.
The performance of the fitted models was assessed using a validation set. The proportion of 
sample that fell below selected centile was used to compare the fit of the training and 
validated model (see supplemental material, Table 6) [23].
Association of lower (3rd, 10th, 25th, 33rd, and 50th) centiles of CD4 cells gain, the WHO 
criteria for immunological criteria, and current CD4 count values at months 4, 10, 16, 22, 
and 28 on ART with subsequent mortality and virological failure
For the outcome of death, person-time started at start of ART (baseline) and was censored at 
the earliest of 1) recorded date of death or 2) at the date of last visit to the clinic. For the 
outcome of virological failure, follow-up time started at ART initiation (baseline) with 
follow-up censored at the earliest of 1) first viral load >1000 RNA copies/ml, 2) date of 
death or 3) date of last visit to the clinic. Cox proportional hazard models were used to 
estimate the crude and adjusted hazard ratios (HR) and their 95% confidence intervals (CI) 
for the association between the lower centiles of CD4 cells count gain at each time point 
with each of the two outcomes considered. A Cox proportional model was also used to 
estimate the strength of the association between WHO definition for immunological failure 
and subsequent mortality and virological failure at each time point. The proportional hazard 
assumption was formally evaluated for all baseline covariates (BMI, WHO clinical stage, 
hemoglobin, CD4 count and age) using the Kolmogorov-type supremum test [24]. Using a 
stepwise backward selection procedure and Wald test, all covariates that did not contribute 
significantly to the fit of each model were dropped. Analyses were done using SAS 9.3 
(SAS Institute, Cary, NC). All tests were conducted using a 2-sided 0.05 significance level, 
without correction for multiple comparisons.
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Sensitivity, specificity, negative and positive predictive values of the WHO definition for 
immunologic failure and CD4 count gain percentile for subsequent mortality and 
virological failure
We used standard definitions [25] to compute the sensitivity, specificity, positive and 
negative predictive values of the WHO definition for immunological failure and the 3rd, 
10th, 25th, 33rd, and 50th percentiles of CD4 count gain for predicting subsequent death and 
virological failure.
RESULTS
Characteristics of the cohort at ART initiation
Of the 21921 non-pregnant adults with baseline CD4 count ≤ 500 cells/mm3 initiating ART 
between April 1, 2004 and April 1, 2014, 1022 died, 745 were lost to follow up or 
transferred out, 391 were administratively censored before reaching 4 months of ART. Of 
the 19980 completing ART for at least 4 months, 14194 had at least one follow-up CD4 
count collected by the seventh month of ART including 9640 at 4 months ±6 weeks post 
ART initiation. A CD4 count result was available at 10, 16, 22, and 28 months ±6 weeks of 
ART for7406, 5577, 4804, and 3446 individuals, respectively.
Among the 9640 included in the analysis of 4 months CD4 gain, 40.6% were male, median 
age was 37.2 [inter quartile range (IQR) 32.0 – 43.5] years, 39.4% were in WHO clinical 
stage III or IV, and almost half (49.7%) had a baseline CD4 count below 100 cells/mm3 
(Table 1). Baseline characteristics of those excluded did not differ substantially from those 
included in the analysis (Table 4, supplemental material).
Cumulative CD4 gains at months 4, 10, 16, 22, and 28 months of ART and their baseline-
standardized distributions
The median cumulative gain in CD4 count increased from four to 28 months on ART, with 
the greatest gain in patients with lowest baseline CD4 counts: from 118 and 36 cells/mm3 at 
4 months to 278 and 148 cells/mm3 at 28 months for those with baseline CD4 count of 50 
and 450 cells/mm3, respectively (Figure 1).
Association between the 3rd, 10th, 25th, 33rd, and 50th percentile of cumulative CD4 gain 
and subsequent time to death
Among the 9640 patients initiated on ART who were retained in the cohort at 4 months of 
follow up and have both baseline and the 4 months CD4 count measurements, 843 (8.7%) 
died after 4 months of ART, with most (48.3%) deaths occurring early (between 4 and 10 
months), 436 deaths occurring after 10 months, 244 after 16 months, 203 after 22 months, 
and 131 after 28 months of ART. Among patients who died, about half had a CD4 gain 
below the 33rd percentile: 46.5% at 4 months, 49.8% at 10 months, 50.0% at 16 months, 
53.7% at 22 months, and 49.6% at 28 months. Low CD4 count gain at any time point was 
associated with subsequent death, with strength of association increasing with decreasing 
centiles of CD4 gain and increasing length of follow-up (Table 2). For example, the HR 
(95% CI) for subsequent death among patients whose CD4 gain at 4, 10, 16, 22, and 28 
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months was below the 3rd percentile, was 2.72 (2.03, 3.65), 3.65 (2.50, 5.33), 4.24 (2.72, 
6.61), 4.89 (2.98, 7.96), and 5.73 (3.26, 10.06), respectively.
Association between the 3rd, 10th, 25th, 33rd, and 50th percentile of cumulative CD4 gain 
and subsequent time to virological failure
In total, 1101 (11.4%) patients experienced virological failure after 4 months, 812 after 10 
months, 662 after 16 months, 633 after 22 months, and 500 after 28 months of ART. Of 
patients who experienced virological failure, 30.5%, 36.1%, 43.8%, 48.9%, and 50.4% had a 
CD4 gain below the 33rd percentile at 4, 10, 16, 22, and 28 months, respectively. As with 
mortality, lower percentiles of CD4 gain at any time point were associated with subsequent 
virological failure with the strength of association increasing with decreasing centiles and 
increasing time on ART (Table 2). For example, the HR (95% CI) for subsequent virological 
failure for patients whose CD4 gain at 4, 10, 16, 22, and 28 months was below the 3rd 
percentile for instance, was 1.48 (1.01, 2.15), 2.69 (1.91, 3.78), 4.00 (2.91, 5.50), 6.93 (5.17, 
9.30), and 4.49 (3.14, 6.43), respectively.
Association between WHO-defined immunologic failure and subsequent mortality and 
virological failure
The proportion of participants meeting the WHO criteria for immunological failure 
decreased with time on ART, from 19.8% at 4 months, to 9.8% at 10 months, 6.7% at 16 
months, 5.2% at 22 months and 4.1% at 28 months. There was a U shape relationship 
between the WHO-defined immunologic failure and baseline CD4 levels with higher 
proportion of patients with lowest and highest baseline CD4 count being identified as 
immunological failure, particularly at earlier follow-up time points (Figure 2). The strength 
of the association between WHO defined immunological failure and subsequent mortality or 
virological failure increased with increasing time on ART (Table 2). The aHR (95% CI) for 
subsequent virological failure was 0.84 (0.71, 1.00) at 4 months and increased to 1.78 (1.44, 
2.20) at 10 months, 3.30 (2.59, 4.21) at 16 months, 5.54 (4.29, 7.15) at 22 months, and 4.78 
(3.46, 6.61) at 28 months. Similarly, the aHR (95%CI) for subsequent death increased from 
1.74 (1.48, 2.04) at 4 months to 5.30 (3.07, 9.16) at 28 months.
Association between current CD4 count and subsequent mortality and virological failure
The median (IQR) current CD4 count at 4, 10, 16, 22, and 28 months was 211 (135, 302), 
256 (177, 356), 307 (218, 416), 340 (244, 460), and 370 (266, 493) cells/mm3, respectively. 
The aHR (95%CI) for subsequent death for every 50 cells/mm3 decrease in the current CD4 
count was similar at all time points, ranging between 1.16 (1.12, 1.20) at 4 months and 1.23 
(1.15, 1.32) at 28 months (Table 2). The aHR (95% CI) for subsequent virological failure 
ranged from 0.97 (0.94, 1.00) at 4 months to 1.16 (1.12, 1.20) at 28 months.
Sensitivity, specificity, and predictive values of lower centiles of CD4 gain and WHO-
defined immunological failure as early indicators of virological failure and death
As expected, sensitivity decreased and specificity increased with lower CD4 gain centiles 
(Table 3). The negative predictive values (NPV) for mortality were high (> 90%) at each 
time point and for all CD4 gain centiles below 50. The positive predictive value (PPV) was 
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low and decreased with increasing time on ART. The NPV for virological failure was also 
high (> 83%) for any centiles but constant over time. The PPV for virological failure tended 
to increase with decreasing centiles and with increasing time on ART. The PPV for 
virological failure was higher than that for mortality, especially at later time points and 
lower centiles. The NPV of the WHO definition for immunological failure was also high, > 
90% for death and > 85% for virological failure. Similarly to low CD4 gain centiles, the 
PPV was low for death (<15%) at all time points. The PPV of the WHO definition for 
immunological failure for subsequent virological failure was lower than that of the third 
percentile of the CD4 gain distribution, especially early after ART initiation.
DISCUSSION
Using data from a large cohort of patients receiving care at an ART clinic in South Africa, 
we constructed percentile curves for CD4 count gain on ART, standardized by baseline CD4 
count. Associations with subsequent death and virological failure showed an increasing 
strength of association with lower centiles and longer time on ART. The use of CD4 gain 
centiles allowed a graded risk assessment of predicted death and virological failure 
compared to the binary yes/no risk profile associated with the WHO definition for 
immunological failure and demonstrated stronger associations with subsequent death and 
virological failure compared to current CD4 count. The positive predictive value however 
remained low, especially for risk of death.
Although virologic monitoring is the gold standard for ART monitoring, randomized control 
trials [5, 26, 27] found routine monitoring of CD4 count to perform similar to virologic 
monitoring in term of prediction of disease progression and mortality. The WHO based the 
preference of viral load over CD4 count monitoring on the poor accuracy of routine CD4 
count monitoring for early detection of treatment failure when using the WHO definition for 
immunological failure [28]. As we demonstrated in this analysis, the poor accuracy may, at 
least in part, be attributable to the high proportion of patients at the extremes of baseline 
CD4 count that are misclassified as immunological failure when using the WHO criteria to 
define immunological failure (Figure 2). The proposed CD4 gain percentiles standardized to 
baseline CD4 count correct this problem and slightly improve the accuracy for early 
detection of treatment failure. While the use of CD4 count gain percentile curve as an 
indicator of subsequent risk of treatment failure still suffered from low positive predictive 
value, especially in the first year of treatment, the CD4 centile curves offer health care 
workers a tool to grade the risk of subsequent death and virological failure in their patients. 
As the CD4 gain drops from the 50th to 3rd centile, the risk of subsequent death increases 
from a 1.6 to 2.7 fold hazard at 4 months of ART and from a 1.9 to 5.7 fold hazard at 28 
months of ART. Similarly, as CD4 count gain drops from the 50th to 3rd centile, the hazard 
of subsequent virological failure increases from a 1.1 to 2.7 fold hazard at 10 months of 
ART and from a 1.8 to 5.6 fold hazard at 22 months of ART. This insight in increasing risk 
could allow heath care workers to target interventions such as more frequent clinical follow-
up, intensified adherence counseling and intensified screening for opportunistic infections to 
those patients at highest risk or patients with increasing risk profiles over time.
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Our analysis has many strengths, including a large sample allowing the use of a training and 
validation dataset, long follow-up (median follow-up time on ART of 54 months), and 
regular availability of viral load measurement. The exclusion of patients initiating ART due 
to lack of regular CD4 counts, transfer out or loss to follow up is a limitation, but the bias 
introduced may be minimal as baseline characteristics of those excluded from the analysis 
did not differ from those included. The restriction to patients receiving ART at a single 
center is another limitation that may limit generalizability. Although, the baseline 
characteristics of patients in our cohort were similar to patients receiving ART in the region 
[16] and the median of current CD4 count at each time point were similar to that reported 
from an analysis of data from 22 sites in Africa, two in Asia, and three in Latin America 
[29], confirmation of the results using data from other facilities in the region or multiple 
regions would strengthen our findings.
In conclusion, while viral load is the gold standard for monitoring the response to 
antiretroviral treatment, [2] viral load assays are not yet routinely available in most settings 
with high burden of HIV. In those setting the WHO recommends that CD4 count be used. 
The percentile curves for monitoring CD4 gain may be a simple tool enabling health care 
workers in resource limited settings to identify patients at increased risk of virological 
failure and death and target interventions at those with highest or increasing risk.
Supplementary Material
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Figure 1. CD4 gain centile curves at month at month 4, 10, 16, 22, and 28 of ART among non-
pregnant HIV-infected adults
Curves were obtained using Box Cox power exponential distribution (BCPE) and the 
generalized additive model for location, scale, and shape.
Model for centile curves at four months (A): BCPE (baseline CD4 count, df(µ) = 12.9, df(σ) 
= 10.5, df(υ) = 8, df(τ)= 3). Model for centile curves at ten months (B): BCPE (baseline 
CD4 count, df(µ) = 3.2, df(σ) = 2.2, df(υ) = 0.5, df(τ)= 0). Model for centile curves at 
sixteen months (C): BCPE (baseline CD4 count, df(µ) = 0, df(σ) = 2.7, df(υ) =0.5, df(τ)=0). 
Model for centile curves at twenty-two months (D): BCPE (baseline CD4 count, df(µ) = 3.9, 
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df(σ) = 2.0, df(υ) = 3.7, df(τ)=0.5). Model for centile curves at twenty-eight months (D): 
BCPE (baseline CD4 count, df(µ) = 2.0, df(σ) = 0.7, df(υ) =1.3, df(τ)=2.0).
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Figure 2. Proportion of patients with WHO-defined immunological failure by time on ART and 
by baseline CD4 count
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CD4 count: median (IQR) * 101 (40, 172)
0 – 100 4792 49.71
101 – 200 3434 35.62
201 – 350 1260 13.07
351 – 500 154 1.6
Hemoglobin: median (IQR) 11.8 (10.20, 13.20)
< 10 g/dl 7148 79.09
>= 10 g/dl 1890 20.91
BMI: median (IQR) § 21.67 (19.23, 24.89)
< 18.5 1541 17.86
18.5–24.9 4999 57.93
25 – 29.9 1427 16.54
30 and up 663 7.68










BMI = Body mass index (kg/cm2), IQR = interquartile range,
**
Totals vary by baseline characteristics due to missing data.
§
The closest value available from 30 days before to seven days after ART initiation.
*
The closest CD4 count measurement from 6 months before to seven days post-ART initiation
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